Video Experimental Relacionado
Updated: Jul 28, 2026
07:47
Experimental Human Pneumococcal Carriage
Published on: February 15, 2013
La vacuna neumocócica en los Estados Unidos. Un análisis crítico es un análisis crítico
JAMA
|September 25, 1981
Resumen
La evidencia actual no apoya la vacunación neumocócica generalizada para los grupos de riesgo. Se necesita más investigación para identificar poblaciones específicas que se beneficien de la vacuna polisacárida neumocócica.
Área de la Ciencia:
- La medicina es la medicina de la medicina.
- Inmunología Inmunología.
- Salud Pública La salud pública.
Sus antecedentes:
- La vacuna neumocócica polisacárida fue aprobada en 1977.
- Las recomendaciones incluyeron a individuos mayores de 2 años en alto riesgo, como los mayores de 50 años, con enfermedades crónicas o en instituciones.
Objetivo del estudio:
- Revisar críticamente la evidencia que respalda las recomendaciones actuales para la vacunación neumocócica.
- Determinar la eficacia y la necesidad de la vacuna neumocócica polisacárida en varias poblaciones.
Principales métodos:
- Revisión de la literatura de la evidencia disponible sobre la incidencia y la mortalidad por enfermedad neumocócica.
- Evaluación de la eficacia de la vacuna en diferentes grupos de riesgo, incluidos los enfermos crónicos, los ancianos y los institucionalizados.
Principales resultados:
- Documentación limitada del aumento de la incidencia o la mortalidad por enfermedad neumocócica en las categorías de alto riesgo recomendadas.
- No hay evidencia convincente de la eficacia de la vacuna en los enfermos crónicos, a excepción de los niños con anemia falciforme.
- Estudios no publicados no muestran ningún beneficio para pacientes ambulatorios, ancianos o institucionalizados.
Conclusiones:
- Los datos actuales no apoyan la vacunación neumocócica generalizada en los Estados Unidos.
- Se requieren más investigaciones para establecer las situaciones específicas en las que la vacuna neumocócica polisacárida es beneficiosa.
Más Videos Relacionados
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
13:47Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
Videos de Conceptos Relacionados
01:30Pneumonia I: Introduction
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia III: Complications and Assessment
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:14Atypical Pneumonia
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
01:29Pneumonia I: Introduction
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...